Related Experiment Videos
Antenatal management of the thrombocytopenias
1Department of Pediatric Hematology Oncology, Cornell University Medical College, New York, New York.
Insights
Antenatal identification and treatment of thrombocytopenia, a common newborn bleeding disorder, can prevent severe fetal hemorrhage. This review covers fetal immune thrombocytopenias, including alloimmune and autoimmune causes.
Area of Science:
- Neonatal Medicine
- Hematology
- Immunology
Background:
- Thrombocytopenia is the most frequent hemostatic disorder in newborns.
- It can lead to life-threatening fetal and neonatal hemorrhage if left untreated.
Purpose of the Study:
- To review fetal thrombocytopenias, focusing on immune-mediated causes.
- To discuss antenatal diagnosis and management strategies.
Main Methods:
- Literature review of fetal thrombocytopenias.
- Focus on immune thrombocytopenias (alloimmune and autoimmune).
- Brief discussion of clinical presentation and differential diagnosis.
Main Results:
- Antenatal identification and treatment are feasible and safe.
- Immune thrombocytopenias are a primary focus, encompassing alloimmune and autoimmune mechanisms.
- Clinical presentation and differential diagnosis are key considerations.
Conclusions:
- Early detection and management of fetal thrombocytopenia can prevent neonatal bleeding.
- Understanding immune mechanisms is crucial for effective antenatal intervention.
- This review provides a foundation for managing fetal thrombocytopenias.
Abstract:
Thrombocytopenia, the most common hemostatic disease of the newborn, can now be safely identified and treated antenatally to prevent life-threatening fetal and neonatal hemorrhage. This article focuses on the fetal thrombocytopenias with emphasis on the most common causes, the immune thrombocytopenias, including alloimmune and autoimmune mechanisms. The clinical presentation and differential diagnosis are discussed briefly.